Has Eugene Depasquale, MD received payments from drug or device companies?

Yes. Drug and device makers reported $104,214 in general payments to Eugene Depasquale, MD across 327 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Eugene Depasquale, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Eugene Depasquale, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Eugene Depasquale, MD

Advanced Heart Failure and Transplant Cardiology · Los Angeles, CANPI 1053593095

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $68,203 of the $104,214 with a category attached, or 65.4%. E.r. Squibb & Sons, L.L.C. accounts for 62.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $60,793 and has fallen 93.5% since, to $3,929 in 2025.

$104,214in general payments, 2019–2025

Across 327 payments — averaging $318.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$65K
Abiomed$26K
Abbott$10K
Medtronic$1K
Impulse Dynamics (USA) Inc.$563
Nuwellis, Inc.$283
plus $490 from 9 others

$92,361in research payments, 2019–2025

Across 32 payments — averaging $2886.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Procyrion, Inc.$44K
Impulse Dynamics (USA) Inc.$18K
E.r. Squibb & Sons, L.L.C.$18K
Abbott$13K

What the payments were for

Consulting fees$3,6003%
Speaking & faculty fees$68,20365%
Travel & lodging$13,76013%
Food & beverage$18,62018%
Education$310%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	67	$65,436
Abiomed	75	$26,087
Abbott	144	$10,042
Medtronic(2 entities)	26	$1,314
Impulse Dynamics (USA) Inc.	4	$563
Nuwellis, Inc.	1	$283
Shockwave Medical, Inc	1	$131
Mallinckrodt Hospital Products Inc.	1	$118
One Lambda, Inc.	1	$67
Ancora Heart, Inc.	2	$51
Takeda Pharmaceuticals U.S.A., Inc.	1	$36
Mallinckrodt Enterprises LLC	1	$31
United Therapeutics Corporation	1	$29
Cardiac Dimensions, Inc.	1	$22
Cvrx, Inc.	1	$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CAMZYOS$61,684
Impella$24,250
THORATEC HEARTMATE 3 LVAS IMPLANT KIT$3,116
OPTIMIZER$1,054
HeartWare HVAD$937
HeartMate 3 Left Ventricular Dev$818
2ND GEN CENTRIMAG PRIMARY CONSOLE$670
CARDIOMEMS$617
CentriMag$465
HeartMate 3 Left Ventricular Assist Device$379
EnSite X$293
Aquadex$283
CardioMEMS HF System$176
MitraClip$138
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$131
UVADEX$118

How this compares

$104,214 in reported general payments places this provider in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California →

Medicare billing

Part B allowed, 2024

$9,335

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lisinopril	12	$96
Hydrochlorothiazide	12	$60

Paid to pharmacies, not to this prescriber.

Other advanced heart failure and transplant cardiology in Los Angeles

Joseph RahmanLos Angeles$101K
Jon KobashigawaLos Angeles$54K
Ajay VaidyaLos Angeles$17K
Aaron WolfsonLos Angeles$16K
Michael FongLos Angeles$9K
Richard WrightSanta Monica$1.7M
James Heywoodla Jolla$1.2M
Hirsch MehtaSan Diego$494K
Teresa de MarcoSan Francisco$366K
Rajeev Mohanla Jolla$357K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →